Skip to main content

Drug Interactions between Cardizem and revumenib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

dilTIAZem revumenib

Applies to: Cardizem (diltiazem) and revumenib

Information for this minor interaction is available on the professional version.

Drug and food interactions

Moderate

dilTIAZem food

Applies to: Cardizem (diltiazem)

Alcohol can lower your blood pressure and add to the effects of dilTIAZem. You may experience dizziness, lightheadedness, fainting, or a rapid heartbeat if you drink alcohol with dilTIAZem, especially when you first start taking the medication or just after a dose increase. Grapefruit juice may also increase the effects of dilTIAZem in some people by increasing its levels in the blood. You may want to limit alcohol intake and avoid excessive consumption of grapefruit and grapefruit juice during treatment with dilTIAZem. However, if you have been regularly consuming grapefruit or grapefruit juice with dilTIAZem, do not alter the amounts of these products in your diet without first talking to your doctor or other healthcare professional. Contact your doctor if your condition changes or you experience increased side effects of dilTIAZem such as headache, irregular heartbeat, swelling, unexplained weight gain, or chest pain. Orange juice is not expected to interact.

Moderate

revumenib food

Applies to: revumenib

High fat content meals may affect the absorption of revumenib. It is recommended that revumenib be taken while fasting or with a low fat meal (approximately 400 calories, with 25% of calories from fat). Grapefruit juice may also increase the blood levels of revumenib which can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Increased levels of [CS1] may also increase the risk of developing a serious and potentially life-threatening condition called differentiation syndrome. Symptoms of differentiation syndrome include: fever, cough, shortness of breath, severe headache, confusion, dizziness, rapid weight gain, swelling, or decreased urination. You should seek immediate medical attention if you develop any of these symptoms and/or symptoms of QT prolongation such as sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with revumenib. The risk and/or severity of other side effects may also increase, including nausea, vomiting, diarrhea, fever or infections. You may need additional monitoring if grapefruit or grapefruit juice are consumed during treatment with revumenib. Talk to a healthcare provider if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Moderate

dilTIAZem food

Applies to: Cardizem (diltiazem)

Using dilTIAZem together with multivitamin with minerals can decrease the effects of dilTIAZem. Talk with your doctor before using dilTIAZem and multivitamin with minerals together. You may need a dose adjustment or need your blood pressure checked more often if you take both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.